A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus

• Status: Completed
• Trial end date: 2020-11-28
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Japanese participants with type 2 diabetes. Side effects and tolerability will be documented. Blood samples will be taken to compare how the body handles the drug and how it affects blood sugar levels. The study will last almost five months for each participant.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Insulin; Insulin, Globin Zinc; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Have type 2 diabetes mellitus (T2DM) for at least 1 year

• Have received a stable daily dose of basal insulin at screening

• Have hemoglobin A1c (HbA1c) greater than or equal to (≥)6.5 percent (%) and less than or equal to (≤)10.0% at screening

• Have a body mass index greater than (>)18.5 and ≤40.0 kilograms per square meter (kg/m²) at screening

Exclusion Criteria:

• Have received a total daily dose of insulin >1.2 units per kilogram (U/kg) of body weight at screening

• Have received insulins except for basal insulins

• Have received sulfonylurea at more than half of the maximum approved dose level

• Have a history of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction or history of significant atopy

• Have had more than 1 episode of severe hypoglycemia within 6 months before entry